ReutersCodex · 实盘不做把握 6/10
北京时间·🕒 发布 00:01:55时区推断·⟳ 抓取 00:02:04·⚡ 决策 07-16 00:16:54 +14m50s·104.0 天前
赛诺菲起诉辉瑞和Moderna称其COVID疫苗侵犯mRNA/LNP专利
诉讼方向上对赛诺菲潜在利好、对辉瑞和Moderna潜在利空，但赛诺菲明确称寻求公平补偿而非禁售。
📄 原文Reuters↗ 原文
Sanofi (SASY.PA) has sued Pfizer (PFE.N) and Moderna (MRNA.O) , alleging that their COVID-19 vaccines infringe several…
不做 赛诺菲（SAN.FR）
诉讼只寻求补偿且金额、胜率、时间均不明，无法形成短线可量化业绩增量，不做。
不做 辉瑞（PFE.US）
看空方向只是长期诉讼赔偿风险，非禁售、非即时业绩下修，且不满足强做空催化，不开空。
不做 Moderna（MRNA.US）
看空方向来自专利诉讼但金额和结果不确定，且未涉及禁售，不满足强做空催化，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-15 · 扩散 medium · price-in 风险 medium ↗
关键理由
- 诉讼方向上对赛诺菲潜在利好、对辉瑞和Moderna潜在利空，但赛诺菲明确称寻求公平补偿而非禁售。
主要风险
- 专利诉讼周期长、金额未披露且结果不确定，短线无法量化为收入或利润增量；对辉瑞和Moderna也不是即时禁售风险。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-15 · 影响 weakens
诉讼目标不是禁售，金额未披露且专利案周期长，对赛诺菲短线利润增量不可量化。
检索:Sanofi sues Pfizer Moderna fair compensation not blocking sales 原文 ↗
原文全文
展开原文 · 2,007 字
Sanofi (SASY.PA) has sued Pfizer (PFE.N) and Moderna (MRNA.O) , alleging that their COVID-19 vaccines infringe several of the French pharmaceutical company's patents.
The two lawsuits filed on Tuesday in New Jersey federal court allege that the blockbuster vaccines violate Sanofi's patent rights in messenger RNA (mRNA) innovations.
The cases add to a web of high-stakes patent lawsuits filed by biotech companies against Pfizer and Moderna over the mRNA technology used in their COVID vaccines.
Spokespeople for Pfizer and Moderna did not immediately respond to requests for comment on Sanofi's new lawsuits on Wednesday. A Sanofi spokesperson said on Wednesday that the company is "seeking fair compensation for use of its patented technology" and not seeking to block sales of the vaccines.
Pfizer and Moderna's shots use molecules called lipid nanoparticles (LNPs) to transport mRNA into the body. Sanofi said in its complaints that their LNP technology infringes patents covering LNP technology developed by its mRNA-focused subsidiary Translate Bio.
Sanofi acquired Massachusetts-based Translate for $3.2 billion in 2021 to bolster its mRNA capabilities.
Companies including GlaxoSmithKline , Bayer and Alnylam Pharmaceuticals have also filed patent lawsuits seeking shares of Pfizer and Moderna's tens of billions of dollars of revenue from COVID-19 vaccine sales.
Moderna sued Pfizer for patent infringement in 2022, in a case that is still ongoing. Pfizer's partner BioNTech countersued Moderna in February, arguing Moderna's next-generation COVID-19 shot, mNEXSPIKE, infringes one of its patents.
The cases are Translate Bio Inc v. Moderna Inc, U.S. District Court for the District of New Jersey, No. 2:26-cv-08690 and Translate Bio Inc v. Pfizer Inc, U.S. District Court for the District of New Jersey, No. 2:26-cv-08697.
For Sanofi: Sarah Chapin Columbia and Sarah Fischer of McDermott Will & Schulte
For Moderna and Pfizer: attorney information not yet available
The two lawsuits filed on Tuesday in New Jersey federal court allege that the blockbuster vaccines violate Sanofi's patent rights in messenger RNA (mRNA) innovations.
The cases add to a web of high-stakes patent lawsuits filed by biotech companies against Pfizer and Moderna over the mRNA technology used in their COVID vaccines.
Spokespeople for Pfizer and Moderna did not immediately respond to requests for comment on Sanofi's new lawsuits on Wednesday. A Sanofi spokesperson said on Wednesday that the company is "seeking fair compensation for use of its patented technology" and not seeking to block sales of the vaccines.
Pfizer and Moderna's shots use molecules called lipid nanoparticles (LNPs) to transport mRNA into the body. Sanofi said in its complaints that their LNP technology infringes patents covering LNP technology developed by its mRNA-focused subsidiary Translate Bio.
Sanofi acquired Massachusetts-based Translate for $3.2 billion in 2021 to bolster its mRNA capabilities.
Companies including GlaxoSmithKline , Bayer and Alnylam Pharmaceuticals have also filed patent lawsuits seeking shares of Pfizer and Moderna's tens of billions of dollars of revenue from COVID-19 vaccine sales.
Moderna sued Pfizer for patent infringement in 2022, in a case that is still ongoing. Pfizer's partner BioNTech countersued Moderna in February, arguing Moderna's next-generation COVID-19 shot, mNEXSPIKE, infringes one of its patents.
The cases are Translate Bio Inc v. Moderna Inc, U.S. District Court for the District of New Jersey, No. 2:26-cv-08690 and Translate Bio Inc v. Pfizer Inc, U.S. District Court for the District of New Jersey, No. 2:26-cv-08697.
For Sanofi: Sarah Chapin Columbia and Sarah Fischer of McDermott Will & Schulte
For Moderna and Pfizer: attorney information not yet available
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。